Figure 1
From: Heparan sulfate mediates trastuzumab effect in breast cancer cells
Cell viability of breast cancer cell lineages treated with trastuzumab. MCF 10A, MCF7, MCF7-HPSE1 and SKBR3 cells were treated with trastuzumab in different doses for 3 days and assayed using MTT, as described in methods. Each point indicates the mean ± standard deviation (SD) of triplicate assays. *P < 0.05 SKBR3 cells, **P < 0.05 MCF7 cells.